56 reports of this reaction
4.0% of all SODIUM NITROPRUSSIDE reports
#5 most reported adverse reaction
UNEVALUABLE EVENT is the #5 most commonly reported adverse reaction for SODIUM NITROPRUSSIDE, manufactured by EXELA PHARMA SCIENCES, LLC. There are 56 FDA adverse event reports linking SODIUM NITROPRUSSIDE to UNEVALUABLE EVENT. This represents approximately 4.0% of all 1,403 adverse event reports for this drug.
Patients taking SODIUM NITROPRUSSIDE who experience unevaluable event should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
UNEVALUABLE EVENT is moderately reported among SODIUM NITROPRUSSIDE users, representing a notable but not dominant share of adverse events.
In addition to unevaluable event, the following adverse reactions have been reported for SODIUM NITROPRUSSIDE:
The following drugs have also been linked to unevaluable event in FDA adverse event reports:
UNEVALUABLE EVENT has been reported as an adverse event in 56 FDA reports for SODIUM NITROPRUSSIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
UNEVALUABLE EVENT accounts for approximately 4.0% of all adverse event reports for SODIUM NITROPRUSSIDE, making it a notable side effect.
If you experience unevaluable event while taking SODIUM NITROPRUSSIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.